寡转移性肾细胞癌立体定向放疗与手术转移灶切除的总生存比较
该回顾性研究纳入2005-2014年瑞典两个肿瘤中心接受立体定向放疗(SRT)、手术转移灶切除(SM)或两者序贯治疗的117例转移性肾细胞癌(mRCC)患者,中位随访63个月。SRT与SM的总生存(中位51个月)无显著差异;ECOG 1 vs 0、颅内靶灶和治疗前观察等待>18个月与总生存独立相关。
要点
- SRT与SM的总生存无显著差异,中位OS均为51个月。
- ECOG 1 vs 0、颅内靶灶和治疗前观察等待>18个月与OS独立相关。
- 15%的根治性治疗患者(n=60)在中位随访87个月时无复发。
核心结论
- 在靶向治疗时代,寡转移性mRCC患者接受SRT的总生存与SM相当。
- 体能状态好、非脑转移且初始观察等待>18个月的患者预后最佳。
研究设计与样本
- 回顾性纳入2005-2014年瑞典两个肿瘤中心的117例mRCC患者,接受SRT(n=57)、SM(n=30)或两者序贯(n=30),中位随访63个月。
主要发现
- SRT与SM的中位OS均为51个月,无显著差异。
- 15%的根治性治疗患者(n=60)在中位随访87个月时无复发。
临床怎么用
- 对于寡转移性mRCC,SRT可作为SM的替代选择,尤其适合不利风险特征常见的患者。
- 体能状态好、非脑转移且经过初始观察等待的患者可能从局部治疗中获益最大。
局限性
- 回顾性研究设计,SRT患者更可能具有不利风险特征,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Investigate effects of stereotactic radiotherapy (SRT) or surgical metastasectomy (SM) on overall survival (OS) in metastatic renal cell carcinoma (mRCC) in the era of targeted agents (TA). MATERIAL AND METHODS: mRCC patients (n = 117) treated with SRT (n = 57), SM (n = 30) or both modalities sequentially (n = 30) at two oncological centres in Sweden in 2005-2014 were retrospectively included. Median follow-up (mFU) was 63 months. RESULTS: A majority had clear cell histology, 1-3 metastases, and ECOG performance status of 0 or 1. Two thirds had intermediate or poor risk and 44% synchronous metastases. 65% received TA. SRT patients were more likely to have adverse risk profiles. Median OS was 51 months without significant differences between SRT and SM. ECOG 1 vs 0 (HR 2.9; CI 1.6-5.2; p < 0.001), intracranial targets (HR 1.8; CI 1.1-3.2; p = 0.03) and watchful waiting >18 months prior to treatment (HR 0.3; CI 0.2-0.6; p = 0.001) were independently associated with OS. 15% of curatively treated patients (n = 60) were relapse-free with mFU of 87 months. CONCLUSIONS: OS after SRT was comparable to SM and longer than expected considering patients with adverse risk profiles were common. Fit patients with non-brain metastases treated after an initial period of watchful waiting had the best prognosis.
引用
- Stenman M, Sinclair G, Paavola P, et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol. 2018. PMID: 29754859. doi:10.1016/j.radonc.2018.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。